Neil Burton / Shutterstock.com
Many NPEs have been using their well-stocked war chests to build massive patent portfolios in the medical technology sector, so right owners need to be prepared for a fresh wave of litigation. Jay Nuttall of Steptoe & Johnson offers some tips.
Patent litigation has been on the rise for decades, with the number of cases filed increasing six times since the 1980s. Most of the growth in the last decade can be attributed to a class of litigants who file lawsuits for a living.
These plaintiffs call themselves patent aggregators or non-practising entities (NPEs), but are sometimes referred to as patent ‘trolls’. They acquire patents with no intention of using the underlying technology. They never manufacture or sell anything.
Instead, many monetise their patents by aggressively filing infringement lawsuits. Because they don’t manufacture anything, they have no need to worry about infringing any competitor’s patents, and have no fear of countersuits. It’s actually the more the merrier: as they pile on cases, they create economies of scale that enable them to bring legal actions at a relatively low cost.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
NPEs, patent trolls, patent, RPX, PwC, IPR,